Holen Sie sich die Stockscreener-App
1.175
12.96%
-0.175
Schlusskurs vom Vortag:
$1.35
Offen:
$1.37
24-Stunden-Volumen:
317.83K
Relative Volume:
2.73
Marktkapitalisierung:
$21.84M
Einnahmen:
$420.00K
Nettoeinkommen (Verlust:
$-26.98M
KGV:
-0.2816
EPS:
-4.1721
Netto-Cashflow:
$-32.01M
1W Leistung:
-30.06%
1M Leistung:
-50.84%
6M Leistung:
-96.28%
1J Leistung:
-99.66%
1-Tages-Spanne:
$1.16
$1.37
1-Wochen-Bereich:
$1.16
$2.0399
52-Wochen-Spanne:
$1.16
$1,030.00
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
1.175 | 21.84M | 420.00K | -26.98M | -32.01M | -4.1721 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
Form 13D/A KALA BIO For: 2 July By Investing.com - Investing.com Nigeria
David Lazar trims KALA BIO (KALA) stake to 3.9% with 719,404 shares - Stock Titan
Price to earnings forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Inc. (KALA) Holds Near Support After Slight Decline: Key Levels in FocusVanna Flow - dars.gov.et
[EFFECT] KALA BIO, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to EBITDA forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Price to book forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
Enterprise value to revenue forward of KALA BIO, Inc. – NASDAQ:KALA - TradingView
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA BIO Inc (KALA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KALA BIO StockLong-term eye-disease strategy in focus - AD HOC NEWS
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
KALA BIO Inc (KALA) Valuation: PE, PB & Fair Value Analysis - TradingKey
KALA BIO Inc. Surges 6.5% as Biotech Momentum Builds: Testing Key Resistance at $2.76Resistance Breakout Stocks - newsline.com
KALA Q4 2025 Earnings: Narrowed Loss Drives 6.5% Stock GainQuarterly Earnings Report - newsline.com
KALA Q4 2025 Earnings: Narrower-than-expected loss highlights cost disciplineAdjusted Earnings Analysis - dars.gov.et
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
KALA BIO Inc. (KALA) Holds Steady Near Support Amid Minimal Price MovementMoving Average Ribbon - newsline.com
KALA BIO (KALA) Holds Steady Near $2.39 Amid Tight Trading RangeUpthrust Pattern - newsline.com
KALA BIO Surges 11%: Approaching Key Resistance at $2.40Wave Truncation - newsline.com
KALA Q4 2025 Earnings: Narrower Loss Beats Expectations Amid Operational ProgressQuarterly Earnings - dars.gov.et
KALA BIO INC (KALA) Stock Chart - ChartMill
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO Q4 2025 Earnings: Wider-Than-Expected Loss but Narrower EPS Surprise Drives Mixed Sentiment - newsline.com
KALAKala Bio Inc Stock Price and Quote - Finviz
Net margin % of KALA BIO, Inc. – LSX:A4243T - TradingView
KALA BIO Shares Slide Over 6% Amid Light Trading and Sector PressureATR Stop - dars.gov.et
KALA BIO (KALA) Smashes Q4 2025 Views with $-33.50 EPSNegative Surprise Momentum - thelegaladvocate.com
KALA BIO (KALA) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-33.50Free Cash Flow Trends - newsline.com
Kala Bio (FRA:27F) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2026) - GuruFocus
Red Light Holland Corp (OP: TRUFF - FinancialContent
KALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 mark - MSN
KALA BIO (KALA) files 13G/A: Baker Bros. reports 2,312 shares post-split - Stock Titan
KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary - TradingView
KALA BIO: Q1 Earnings Snapshot - 10TV
KALA: Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions - TradingView
KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KALA BIO (NASDAQ: KALA) slashes R&D spend and pivots to Researgency AI platform - Stock Titan
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Total assets of KALA BIO, Inc. – LSX:A4243T - TradingView
Discontinued operations of KALA BIO, Inc. – TRADEGATE:27F - TradingView
Cash from operating activities of KALA BIO, Inc. – FWB:27F - TradingView
Asset turnover of KALA BIO, Inc. – FWB:27F - TradingView
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):